partnering to advance global health - sanofi€¦ · digital page 13 gem general medicines &...

PARTNERING TO ADVANCE GLOBAL HEALTH

Contents

Partnering with UsPartnering: Sharing Expertise to Drive Innovation

page 1

Sanofi at a GlanceSanofi, a Global Healthcare Leader

page 2

Strategic PrioritiesStrategy 2015-2020

page 3

Diabetes & CardiovascularDiabetes

page 4

Cardiovascular

page 5

Sanofi GenzymeRare Diseases

page 6

Multiple Sclerosis & Neuroscience

page 7

Immunology

page 8

Oncology

page 9

Sanofi PasteurVaccines

page 10

Infectious DiseasesInfectious Diseases

page 11

PlatformsDrug Discovery & Biologics

page 12

Digital

page 13

GEMGeneral Medicines & Emerging Markets

page 14

CHCConsumer Healthcare

page 15

Partnering ModelPartnering Capabilities

page 16

Alliance ManagementValue Creation Through Partnerships

page 18

Partnering Opportunities Contacts

page 20

1 — PARTNERING WITH SANOFI

Partnering with Us

Partnering: Sharing Expertise to Drive Innovation

“Our organization is made up of many talented

individuals with varied skills and experiences.

Most importantly, everyone has a deep

commitment to making Sanofi one of the best

pharmaceutical companies in the industry.

We all want to bring important medicines

to patients in need, all over the world.

This is core to what we do and think about.”

Muzammil Mansuri Executive Vice-President Strategy & Business Development

We are a global life sciences company committed to improving access to

healthcare and supporting the people we serve throughout the continuum of care.

From prevention to treatment we transform scientific innovation into healthcare

solutions in human Vaccines, Rare Diseases, Multiple Sclerosis & Neuroscience,

Oncology, Immunology, Infectious Diseases, Diabetes & Cardiovascular and

Consumer Healthcare. Our diversity and global reach is supported by our strong

presence in Mature and Emerging Markets.

Business Development is a key component of our strategy. In order to bring

life-changing treatments to unmet healthcare challenges, we will always pursue

innovation. We continuously seek innovative collaborations to build alliances

that create value for global health.

Collaborations are, for us, one of the crucial elements of success. We are committed

to share our skills and projects with the best professionals and companies in each

of our areas of interest, wherever they are. We have signed agreements with partners

around the world, strengthening our network of innovation excellence to deliver

great quality products.

All activities critical to Business Development have been brought together into

one global, integrated group. We are on a journey dedicated to make a difference

on people’s daily life, wherever they live and enable them to enjoy a healthier life.

We invite you to join us on this exciting and worthwhile endeavor to offer innovative

solutions that protect health, enhance people’s quality of life and improve access

to healthcare around the world.


Sanofi at a Glance

SANOFI, a Global Healthcare Leader committed to preventing and

treating diseases around the world

+100,000employees in more

than 100 countries

6key innovations

between 2015-2020

Health solutions

available in

+170 countries

5.2 billion invested in R&D

in 2016

Pharmaceuticals

86.5%€29,244 M

Vaccines

13.5%€4,577 M

Europe(2)

25.7%€8,679 M

United States

36.6%€12,391 M

Emerging markets(3)

28.4%€9,593 M

Rest of the world(4)

9.3%€3,158 M

Company sales

by activities(1)

Company sales

by geographical areas(1)

€33.8 Bn company sales(1)

(1) Following the closing of the business swap with Boehringer Ingelheim, which consisted of an exchange of Sanofi’s Animal

Health business and BI’s Consumer Healthcare business, those figures are presented excluding Animal Health business.

(2) Western Europe + Eastern Europe (except Eurasia).

(3) World excluding U.S., Canada, Western & Eastern Europe (except Eurasia), Japan, South Korea, Australia, New Zealand

and Puerto Rico.

(4) Japan, Canada, South Korea, Australia, New Zealand, Puerto Rico.


Strategic Priorities

Strategy 2015-2020

Our 5 Global Business

Units

Sanofi GenzymeRARE DISEASES MULTIPLE SCLEROSIS & NEUROSCIENCE IMMUNOLOGY ONCOLOGY

Sanofi PasteurVACCINES

General Medicine & Emerging MarketsGENERICS MATURE PRODUCTS

Consumer Healthcare

Diabetes & Cardiovascular

1. RESHAPE THE PORTFOLIORestructure our portfolio to focus

on human health• Sustain leadership and consolidate operations

in areas where Sanofi has substantial expertise

and experience: Diabetes & Cardiovascular,

Vaccines, Rare Diseases, and Emerging Markets

• Build competitive positions and develop

expertise in Multiple Sclerosis & Neuroscience,

Oncology and Immunology

• Position Sanofi as a leader in Consumer

Healthcare

3. SUSTAIN INNOVATION IN R&DEnhance R&D innovation to develop

our drugs and vaccines• Products that make a real difference to the

doctors writing prescriptions, payers reimbursing

their cost, and the patients who should,

ultimately, receive the best possible care

• Devote substantial resources to the most

promising projects in our R&D portfolio

• Foster existing R&D collaborations and

increase capacity for external innovation

2. DELIVER OUTSTANDING LAUNCHESSuccessfully launch our major

new products• Innovation driven by new medicines, such

as Toujeo®, Praluent®, and Dengvaxia®

• Prepare the introduction of the insulin glargine/

lixisenatide combination SoliquaTM/SuliquaTM

for diabetes, Dupixent® for atopic dermatitis,

and Kevzara® for rheumatoid arthritis

4. SIMPLIFY THE ORGANIZATIONStreamline and simplify

our organization teams• Establish five global business units to improve

collaboration between R&D and business

operations, thereby fast-tracking the time to

market for our innovations

• Globalize and integrate all key functions

including Research & Development

and Strategy & Business Development



DiabetesWe are a global leader in Diabetes due to our rich

history and pipeline and our ambition is to expand

care to the next level.

Our teams are focused on developing treatments

that will alter the progression of cardio-metabolic

disease and reduce the risk of debilitating

complications that are challenging for individuals

and healthcare systems.

Furthermore, we strive to deliver integrated

solutions that fit into the lives of people living

with these chronic illnesses, enabling better

disease management, better outcomes

and reduced costs.

We deliver innovative Diabetes

care solutions to people

worldwide by benefiting from

a global commercial and

industrial footprint in this area.

Disease modification in T1D and T2D

• Beta cell replacement

• Immune intervention in T1D

• Beta cell regeneration and protection

• Insulin sensitizers

Obesity

• GI and multi-agonist peptides

• Oral weight management

• Obesity devices

Translational research

• New cardio-metabolic targets

• Predictive biomarkers

Complications

• Cardiovascular risk in diabetes patients

• NASH

• Diabetic kidney disease

• Diabetic neuropathy

Insulins and Peptides

• Glucose sensing insulin

• Small molecule oral GLP-1

• Metabolic peptides with novel MOA

Drug Delivery

• Oral delivery for insulin and peptides

• Device technology



CardiovascularCardiovascular disease is the number one cause

of death globally, accounting for nearly 30%

of all deaths.

We have significant experience from

the development of innovative brands in

this therapeutic area and we remain committed

to developing new therapies by building on

our strong legacy.

We launched Praluent®

(alirocumab), an innovative

treatment helping adult patients

with hypercholesterolemia

to reduce their level of bad

cholesterol, result of our

collaboration with Regeneron.

Cardiomyopathies

• Hypertrophic Cardiomyopathy

• Dilated Cardiomyopathy

• Other forms of Cardiomyopathy

Heart Failure

• Acute Heart Failure.

• Chronic Heart Failure with Reduced

Ejection Fraction (HFrEF)

• Chronic Heart Failure with Preserved

Ejection Fraction (HFpEF)

Hyperlipidemia

• Orally bioavailable PCSK9 inhibitor and

novel oral drugs to lower LDL-C

• Oral or injectable agents for other lipid

disorders, such as high Lp(a) and

hypertriglyceridemia

• Specific therapies for diabetes-related

cardiovascular disease

Vascular Disease

• Peripheral Arterial Disease, including

critical limb ischemia and intermittent

claudication

• Microvascular disease


Sanofi Genzyme

Rare DiseasesFor over three decades we have discovered

and developed transformative therapies

for people with rare and special unmet

medical needs.

Our focus is on diseases with well-defined

mechanisms and high unmet needs.

We pioneered the delivery

of transformative therapies

to people with Rare Diseases,

providing hope where there

was none before.

Metabolic/Pediatric

• Glycogen storage disorders, such as

Pompe disease

• Lysosomal storage disorders, including

those with neurometabolic manifestations

• Leukodystrophies

• Hyperaminoacidemias

• Hyperammonemias (e.g. urea cycle

disorders)

Hematology

• Amyloidoses

• Gaucher disease

• Hemophilia

Nephrology

• Alport syndrome

• Fabry disease

• Polycystic kidney disease and other

ciliopathies

Neuromuscular

• Dystrophies, such as Duchenne,

alpha-dystroglycanopathy, myotonic and

facioscapulohumeral muscular dystrophy

• Pompe disease

Pulmonary

• Cystic fibrosis

Bone

• Achondroplasia

• Osteogenesis imperfecta

Gene Therapy

• AAV capsids with improved tropism for the

CNS, liver and muscle


Sanofi Genzyme

Multiple Sclerosis & NeuroscienceDebilitating neurodegenerative diseases of the

central nervous system including Multiple Sclerosis,

Parkinson’s Disease, Alzheimer’s and Huntington

represent significant unmet medical need, heavily

impacting patients and their families.

Our team includes

internationally recognized

scientists in Neurology,

Rare Diseases, and

Neuroimmunology, working on

slowing neurodegeneration,

modulating neuroinflammation,

and facilitating neuroprotection,

repair and remyelination.

Multiple Sclerosis

• Immunomodulation

– Drug candidates targeting lymphocytes

with novel mechanisms of action,

with potential for high efficacy and

manageable safety

• Neuroinflammation

– Drug candidates targeting CNS

inflammatory milieu, microglia and

astrocytes

• Remyelination and Neuroprotection

– Drug candidates targeting

oligodendrocyte differentiation,

remyelination and neuroprotection

• Symptom Management

– Drug candidates targeting MS-related

cognitive and behavioral symptoms,

preferably with clinical proof of concept

Neuro Rare Diseases

• Gene replacement strategies and

therapeutics for rare monogenic

neurodegenerative diseases, including

Gaucher related Parkinson’s, Huntington

Disease, Amyotrophic Lateral Sclerosis,

neurodevelopmental disorders and

Friedreich’s ataxia

• Therapeutics and novel targets for

peripheral neuropathies including Charcot-

Marie-Tooth Disease

Neurodegeneration

• Small molecules or biologics targeting

tau or alpha-synuclein that reduce

accumulation and spread of pathology

• ApoE4 correction or lowering approaches

• Normalization of insulin resistivity

and glucose metabolism

• Therapeutics and novel targets to restore

mitochondrial function

• Small molecules targeting CNS inflammatory

milieu, microglia and astrocytes

Translational Neuroscience and technologies

• Biomarkers to predict disease progression,

stratify patient populations, monitor

therapeutic interventions

• PET ligands for misfolded proteins,

neuroinflammation, and to demonstrate

therapeutic target engagement

• Methods for quantifying synaptic plasticity

and synaptic loss, neuroprotection,

or assessing remyelination in vivo

• AAV capsids for systemic or intrathecal

administration, widespread transduction of

brain cell types

• Methods of enhancing transit of

therapeutics across the Blood-Brain Barrier


Sanofi Genzyme

ImmunologyWe seek new therapeutics to normalize immune

responses in immune-mediated disorders

such as rheumatic, respiratory, inflammatory

skin and gastrointestinal diseases.

Our focus is on biologics, small molecules

and nucleic acid-based approaches.

We launched Dupixent®

(dupilumab), a first-in-class

biologic drug in allergic

dermatological and pulmonary

disorders, result of our

collaboration with Regeneron.

Dermatological and Pulmonary Disorders

• Atopic dermatitis

• Psoriasis

• Severe asthma

• Chronic rhinosinusitis

• Idiopathic pulmonary fibrosis

• Chronic Obstructive Pulmonary Disorder

(COPD)

• Scleroderma

Rheumatological Disorders

• Rheumatoid arthritis

• Psoriatic arthritis

• Ankylosing spondylitis

• Systemic Lupus Erythematosus

Gastrointestinal Disorders

• Eosinophilic esophagitis

• Inflammatory Bowel Disease

(Crohn’s Disease, ulcerative colitis)

Novel approaches for modulation of the immune response in Autoimmune Disease

• Normalization of aberrant immune

responses in allergic disease,

including “atopic march”

Technologies to increase mechanistic understanding of Autoimmune Disease

• Identification, characterization

and validation of biomarkers

for patient stratification and monitoring

of clinical responses


OncologyCancer remains a leading cause of death

worldwide.

We are building on our strong heritage

in oncology research to pursue curative

approaches.

Collaborations focusing on novel therapeutic

approaches are a key part of our strategy.

We are rebuilding a competitive

position in Oncology through

a range of innovative

collaborations in the emerging

fields of immuno-oncology

and targeted therapies.

Overcoming Immunosuppression

• Modulation of immunosuppressive

components in the tumor

microenvironment

• Suppressive mechanisms within myeloid

lineage cell types

• T cell invasion and expansion Modalities

outside “classical” immune checkpoints

Cancer dependency related therapies

• Drugs or novel targets targeting:

– K-RAS directly or cancers where K-RAS

is implicated

– Oncogenic drivers and pathways

currently lacking therapy

– Co-dependency or synthetic lethality

• CRISPR/CAS9 based target identification

platform

• Targeted therapy resistance (induced

or intrinsic)

• Novel lineage targets and drugs targeting

them

Active Immunization and Antibody directed Tumor Targeting

• Stimulation of functional activity of antigen

presenting cells

• Redirection of immunity against tumors

using cell engagers & immuno-conjugates

• Innovative PRRs (pattern recognition

receptors) agonists and adjuvants

• Devices for direct intra-tumoral/intra-nodal

injection

Other Interests

• Translational Medicine and biomarkers

to support pipeline

• Immune profiling methodologies in

preclinical and clinic (immuno-monitoring).

• Novel-novel combinations

• Preclinical platform to test and validate

immuno-oncology combinations

• Molecular entities with potential

for transformative benefits

• Commercial opportunities synergistic with

current portfolio: prostate cancer, colorectal

cancer, gastric cancer, Multiple Myeloma,

TNBC (triple negative breast cancer),

NSCLCs (non-small cell lung cancer)

Sanofi Genzyme


Sanofi Pasteur

VaccinesAs a world leader in the field of prevention,

we offer a broad range of vaccines protecting

against 21 infectious diseases.

Our focus is on developing safe and effective

vaccines with a single or combined target against

complex diseases.

We provide more than 1 billion

doses of Vaccines each year,

making it possible to immunize

more than 500 million people

across the globe.

Vaccines, Monoclonal Antibodies & Supporting Technologies

• Novel antigens and methods for antigen

discovery

• Novel conjugation technologies.

• Vaccine vectors suitable for nasal

or oral use

• New ways to administer vaccines

Tools for improving Vaccine and Monoclonal Antibody research, development and production

• Genomics and proteomics technologies

• Prokaryotic or eukaryotic cell lines for

antigen production

• Fermentor and bioreactor technology

• Disposable systems

• Downstream processing

• Process automation

• Preservatives and stabilizers

• Bioinformatics techniques

Vaccine immune responses’ Enhancers

• Adjuvants and immunomodulators

• Vaccine vectors and delivery systems

• Biological and immunological studies

to further characterize adjuvants and

immunomodulators

Characterization and assay of immune responses and Disease Markers

• Animal models of human diseases

• In vitro models of human tissues, including

the immune system

• Biological markers


Infectious Diseases

Infectious DiseasesOur focus is on game-changing, breakthrough

innovations in areas of highest medical need

such as severe bacterial and parasitic infections

as well as acute and chronic viral infections.

We have a rich history in

the area of Infectious Diseases

and have signed the Davos

declaration with other leading

international companies to take

comprehensive action against

drug-resistant infections.

Products

• Antiviral agents against HBV, HIV,

and respiratory viruses

• Anti gram-negative antibiotics, potentially

with a new MoA for severe infections

• Tuberculosis or Malaria agents,

with potential for contributing

to affordable regimens and addressing

resistance issues

• Immunomodulation, anti-virulence agents

• Agents could be innovative small

molecules, biologics or natural products

Targets

• Immunomodulation, anti-virulence

approaches

• Novel bacterial or viral targets relevant

for disease resolution

Technologies

• Innovative approaches (whole cell

screenings, high content,

chemonomics…) for identification

of new antimicrobial agents


Platforms

Drug Discovery & BiologicsDrug Discovery identifies bioactive synthetic

molecules and advance them to the clinic.

Drug Discovey covers fields such as lead

generation biology, structural biology,

computational design, medicinal chemistry and

pharmacokinetics.

Biologics research, develop and manufacture

recombinant enzymes, mAbs, antibody-drug

conjugates, insulins, fusion proteins, gene

and nucleic acid therapeutics.

Biologics molecules make up more than 50%

of Sanofi’s development pipeline.

Drug Discovery– Next generation screening techniques

– Innovative chemical matter: small molecules,

peptides, macrocycles, natural products

– Target validation: gene editing, compound

de-orphaning technologies

– Advances in computational chemistry and

structural biology

– Novel drug delivery

– Prediction of stability, toxicity and

pharmacokinetics in silico, in vitro or in vivo

– Disease relevant 3D tissue cultures

– Systems biology/pharmacology/toxicology

models

– Identification of drug efficacy biomarkers

– Target engagement in living systems

Biologics

• Monoclonal Antibodies and

Alternative Scaffolds

– Technologies and platforms to improve the

generation and manufacturing of bi- and

multispecifics mAbs and cell engagers

– New technologies for mAb optimization,

(i.e. Fc engineering, enhancing antibody

valency, improving developability, viscosity

reduction, extending half-life)

– Novel and future biologics: non-mAbs

scaffolds, modular biologics, advanced

structure based design, synthetic biologics

– Prediction of immunogenicity and biophysical

liabilities: aggregation, high viscosity, etc

• Delivery

– Tissue-specific delivery of nucleic acid

– Therapeutics to organs other than liver

– Alternatives to GalNac ligand for

liver targeting

– Targeting

– Cell penetrating biologics, mAbs

and protein therapeutics

– Therapeutics

– Delivery of biologics across physiological

barriers: BBB, GI, skin, lungs

• Development and Manufacturing

– Improving biophysical properties of mAbs:

aggregation, viscosity, syringeability,

solubility, etc.

– Mammalian cell technologies to improve

expression and production of recombinant

proteins

– Predictive tools for biomanufacturing:

behavior under process conditions, process

simulation, technologies for online analysis

and process controls for production of

biologicals breakthrough technologies in

protein purification, e.g. column free

downstream processing

– Production of AAV-based gene therapies,

especially expression and packaging

We remain on the cutting edge

of discovery, development and

manufacturing by incorporating

external innovation into our

internal platforms.


Platforms

DigitalWe believe digital will transform the way therapies

are discovered, developed, and brought to

patients, providers, and payers.

Additionally, digital solutions represent new ways

of improving care at a reduced cost with improved

patient/consumer experience.

In particular for Diabetes, integrated care solutions

can bring critical enablers together and empower

people to live the life they want with better care

quality and outcomes.

We seek partners who believe in our ambition,

our global reach, our deep scientific expertise

and our commercial expertise.

We are a leader in Digital

health solutions, partnering with

companies like Science 37,

Verily Life Sciences, and Voluntis.

Drug Discovery and Development

• Distributed studies

• Patient recruitment/engagement

• Wearable sensors

• Optimizing site selection and/or

study start-up

• Decision support and visibility tools

Multichannel Engagement through Drugs plus Digital Solutions

• Patient engagement

• Medication management

• Patient, clinical, population health

decision support tools

• Coaching, nursing support

• Disease management

• Telemedicine

• Wearable sensors, connected devices

Data & Analytics from R&D to RWE (Real World Evidence)

• Target identification and disease

understanding

• Integrated laboratory solutions

• Predictive modeling

• ETL stack/infrastructure

• Patient stratification

• Drug selection/precision medicine

Diabetes Integrated Care

• Drug delivery devices; connectivity

solutions

• Innovative glucose monitoring solutions

• Decision support solutions for patients,

healthcare professionals and payers

(e.g. titration, treatment adherence,

medical algorithms)

• Behavior and food monitoring

and coaching solutions

• Digital engagement solutions, enrollment

solutions

CHC 360º Health Management

• Technologies that encourage healthier

habits, allow self-monitoring and provide

personalized recommendations, especially

for products in our core categories

– New tools for diagnosis, data-collection,

self-monitoring and adherence to therapy

– Digital Healthcare solutions for a closer

interaction with the consumer

– Solutions to provide tailor-made

recommendations considering individual

consumer needs


GEM

Mature Markets

• Opportunities to enhance our existing

franchises, through addition of innovative

late stage or commercial products or

acquisition of complementary established

products

Emerging Markets

• Late stage or commercialized products

that complement our broad portfolio

General Medicines & Emerging MarketsWe manage established products and generics

globally as well as innovative pharma products

in Emerging Markets.

Emerging Markets are all those outside the Mature

Markets of North America, Europe, Japan,

Australia, New Zealand and South Korea and

are divided into five Regions: Latin America, China,

Africa, Eurasia & Middle East and South Asia.

Our set of capabilities as a global biopharma

company combined with an unparalleled

footprint in Emerging Markets makes us

the partner of choice.

We can offer flexible deal terms to accommodate

our partners’ strategic needs. Leadership in Emerging Markets

• Leading franchises in Diabetes & Cardiovascular,

Thrombosis, CNS, Anti-Infectives and Specialty

Care (especially in Rare Diseases)

• One Stop Shop: Strong footprint across all key

Emerging Markets

• Integrated capabilities: R&D, Medical,

Regulatory, Market Access, Sales & Marketing

• Local manufacturing, packaging and distribution

We have an impressive presence

in Emerging Markets as a result

of decades of commitment to their

diverse needs.


Consumer HealthcareOur ambition is to become the best global

Consumer Healthcare business embracing

transformative healthcare solutions and

technologies.

We are among the top global

players in Consumer Healthcare,

providing new and compelling

product choices to people.

Core Categories and Adjacent Subcategories

• Differentiated, consumer relevant

innovations that have a significant growth

potential in our core categories: Cough &

Cold and Allergy, Digestive Health,

Nutritionals and Pain (including pediatric

solutions)

– Licensing and/or R&D collaborations for

consumer solutions that address relevant

needs and provide differentiated and

superior claims

– Licensing, distribution or acquisition deals

for distinctive brands and products on a

global, regional or local level which

broaden or strengthen our offer to

consumers

– Specific partnering options for superior

consumer solutions adjacent to our core

categories, including mobility, sleep and

liver health

White spaces

• Great choices outside our core categories

to enter and shape consumer relevant

categories with strong growth perspectives

– Access to Rx-to-OTC switch candidates

including first-in class switch candidates

to address unmet consumer needs

– Access to superior clinically proven

compounds including generic Rx-to-OTC

switch candidates and products that allow

addressing unmet consumer needs

– Licensing, distribution or acquisition deals

for distinctive brands and products on

a global, regional or local level which

enlarge our presence in attractive

markets and categories without current

significant footprint

CHC


Partnering Capabilities

Changing the Ways Sanofi Partners

Partnering Model

Pushing for Innovation

More than

16,000employees

committed to R&D

15.3%of company sales invested

in R&D, increasing

annual R&D investments

up to €6 bn by 2020

46projects in the R&D pipeline, as of April 2017

Between 2015-2020

6major innovations inDengue, Cardiovascular,Diabetes, Rheumatoid Arthritis, Atopic Dermatitis, Asthma

83industrial sites

Approximately

40,000industrial employees

Approximately

€3 bninvested over

three years

Cutting-edge Manufacturing Network

Producing

BiologicsPills/ChemistryDelivery Devices

2015-2020

Strategic Roadmap

To create long-term value

New Organizational Model

To drive focus

and simplification

Accelerate Business

Development and Strategic

Alliances activities

Strengthen and

grow the portfolio


• Licensing, Collaborations and M&A

• Target products and technologies supportive to R&D

• Early to late stage technology/products

The corporate partnering arm of Sanofi invests in opportunities in alignment with Sanofi’s

strategic priorities to maximize value creation. Our objective is to seek and execute

external growth and collaboration opportunities to reshape our portfolio and support

R&D innovation. Business Development & Licensing has global scope, across all business

units and therapeutic areas.

Business Development & Licensing has the flexibility to pursue a broad range of deal

structures to support the strategic intent of the partnership; from in- and out-licensing,

R&D collaborations and M&A (asset/company acquisitions and divestitures) to models

such as joint ventures, commercial collaborations and other types of strategic alliances.

• Straight equity participation

• Early stage technologies/products

• Strategic interest

The corporate venture capital arm of Sanofi invests in early stage healthcare companies

with promising new products and technologies of strategic interest to Sanofi. As a

strategic partner, Ventures invests globally and directly in innovative start-ups aligned

with Sanofi’s areas of interests, including rare genetic diseases, vaccines, transformative

therapies addressing other unmet medical needs, and digital health and other

breakthrough therapies. Ventures has an expedited decision-making process enabling

rapid and clear decisions.

In addition to equity financing, Ventures provides strategic and technical input by

leveraging the established expertise of Sanofi teams in science, preclinical and

clinical development and regulatory strategy when helpful. Ventures’ success is driven

by our ability to invest in areas where we have a unique voice and insight, and then

to engage actively, what could lead to future strategic collaborations and product

opportunities.

• Company co-creation

• Equity participation and first partner

• Deal size tailored to R&D plan

Sanofi’s company co-creation and incubation vehicle has a primary goal of

accelerating the delivery of transformative treatments to patients in need while adding

innovative products to the Sanofi pipeline. Sunrise partners for innovations that are best

developed through focused efforts by entrepreneurs in new start-up biotech companies,

and works across all therapeutic areas. Sunrise seeks programs based on novel

biological insights and the typical stage of the product opportunities at time of initial

investment is 2-4 years to IND.

Sunrise is both an equity investor and a collaborative partner, taking a risk-sharing,

science-driven investment approach captured in a jointly developed research and

development plan. Direct Sunrise investment in the company focuses on aligned interests

of all involved parties. Through Sunrise, Sanofi secures product rights, but notably the

new company retains significant rights and independent value creation opportunities.

Sanofi’s strategic interests, supported by strong internal sponsorship, drive a close

partnership with the entrepreneurs. Further, Sunrise bridges innovative science with

expert capabilities and committed resources from Sanofi. Our close and collaborative

relationship provides important validation to any nascent life sciences company.

Partnering Model

Deal Making Flexibility


Value Creation through Partnerships

Alliance Management

We believe that Alliance Management is the keystone of any sound and successful collaboration.

For this reason, we have a dedicated team of Alliance Managers, working across the globe to fulfill

the mission of maximizing the value through collaborative engagement, management of risk, actionable

assessment and agile governance.



Onduo – Verily

Joint venture created through Sanofi and Verily’s

diabetes-focused collaboration to develop a

comprehensive diabetes management platform.

Onduo’s mission is to help people with diabetes

live full, healthy lives by developing comprehensive

solutions that combine devices, software,

medicine, and professional care to enable simple

and intelligent disease management.

The company will leverage Verily’s experience in

miniaturized electronics, analytics, and consumer

software development, and Sanofi’s clinical

expertise and experience in bringing innovative

treatments to people living with diabetes.

Lexicon Pharmaceuticals

Collaboration and license agreement in diabetes on

sotagliflozin, and investigational new oral medicine

in phase III studies for patients with diabetes.

MyoKardia

Worldwide collaboration to discover and develop

first-of-its-kind targeted therapeutics for heritable

heart diseases known as cardiomyopathies, the

most common forms of heart muscle disease. The

collaboration builds upon MyoKardia’s pioneering

science, which hopes to correct the disruptive effects

that disease mutations have on heart muscle

contraction.

Sanofi Pasteur (Vaccines)

MedImmune

Agreement to develop and commercialize a

monoclonal antibody (MEDI8897) for the

prevention of Respiratory Syncytial Virus (RSV)

associated illness in newborns and infants.

Walter Reed Army Institute of Research (WRAIR)

Cooperative Research and Development

Agreement (CRADA) for the technology to

advance WRAIR’s Zika purified, inactivated virus

(ZPIV) vaccine.

General Medicines & Emerging

Markets

JHL Biotech

Collaboration for the development and

commercialization of biological therapeutics in

China and with potential international expansion.

Consumer Healthcare

CR Pharmaceutical

Strategic alliance to explore consumer healthcare

opportunities in China.

Sanofi Genzyme (Specialty Care)

ImmuNext

Agreement focused on the development of a

novel CD40L monoclonal antibody (INX-021)

with the potential to treat a range of autoimmune

diseases including Lupus and Multiple Sclerosis.

Alnylam

Collaboration in rare diseases to develop and

commercialize RNAi therapeutics targeting

transthyretin (TTR) for the treatment of transthyretin-

mediated amyloidosis (ATTR) in Japan and other

Asia-Pacific countries, that has been extended in

January 2014 by forming a transformational

alliance focused on the advancement of RNAi

therapeutics as genetic medicines.

Regeneron

Since 2007, Regeneron and Sanofi have

collaborated to discover, develop, manufacture

and commercialize fully human monoclonal

antibodies. In 2015, Sanofi and Regeneron entered

into a new global collaboration in the emerging

field of immuno-oncology to discover, develop

and commercialize new antibody cancer

treatments. This long-standing, broad alliance has

enriched our pipeline with products such as

Praluent®, Dupixent®, Kevzara® and a PD-1 inhibitor.

Innate Pharma

Research collaboration and license agreement in

immuno-oncology for new biospecific antibodies

using Innate Pharma’s technology and Sanofi’s

technology and tumor targets.

BioNtech

Research collaboration and license agreement in

immuno-oncology leveraging the scientific expertise

of the two organizations to discover and develop up

to five cancer immunotherapies, each consisting of

a mixture of synthetic messenger RNAs (mRNAs).

Voyager Therapeutics

Collaboration to develop gene therapies for

neurological diseases such as Parkinson’s, Friedreich’s

ataxia and Huntington’s disease combining our

experience in the field of adeno-associated virus (AAV)

gene therapy and Voyager’s AAV product engine to

develop therapies for multiple programmes.

Platforms

Science 37

Agreement to use its MetasiteTM model and NORA®

technology for digital clinical trials to improve

recruitment and reduce trial times.

Alliance Management


We invite you to contact us about partnering opportunities

according to your area of interest.

Diabetes & CardiovascularLoic HAMEON – [email protected]

Diabetes: Ulrich WENDT – [email protected]

Cardiovascular: Michael DRAPER – [email protected]

Sanofi GenzymeMark BARRETT – [email protected]

Rare Diseases: Brian BRONK – [email protected]

Multiple Sclerosis & Neuroscience: Isaac VEINBERGS – [email protected]

Oncology: Kaan CERTEL – [email protected]

Immunology: Adam KEENEY – [email protected]

Sanofi PasteurJean-Louis GRUNWALD – [email protected]

Vaccines: Roman CHICZ – [email protected]

Infectious Diseases

Anne DAGALLIER – [email protected]

PlatformsDrug Discovery: Peter HAMLEY – [email protected]

Biologics: Shiv KRISHNAN – [email protected]

Digital: Rachel SHA – [email protected]

General Medicines & Emerging MarketsLatin America: Nicolas GOBEILL – [email protected]

China: Matthieu MERLIN – [email protected]

Africa, Eurasia & Middle East, South Asia: Eric SOL – [email protected]

Consumer HealthcareOliver FREICHEL – [email protected]

Contacts

Partnering Opportunities

This 2017 Sanofi document was designed and produced by the Sanofi Communications Department and .

Photo Credits:

Cover: Getty Imagebank; p. 4: Christian Fleury/Capa Pictures; p. 5: Vincent Moncorgé; p. 6: Pierre-Olivier/Capa Pictures; p. 7: Pierre-Olivier/Capa Pictures;

p. 8: Cedric Arnold/Capa Pictures; p. 9: Randy Monceaux; p. 10: Christian Fleury/Capa Pictures; p. 11: Pierre-Olivier/Capa Pictures;

p. 12: Pierre-Olivier/Capa Pictures; p. 13: Getty Imagebank; p. 14: Diego Cervo/Fotolia; p. 15: Piotr Redlinski/Capa Pictures.

Forward-Looking Statements:

This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking

statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements

regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and

potential, and statements regarding future performance. Forward-looking statements are generally identified by the words ”expects”, "anticipates",

”believes”, ”intends”, ”estimates”, ”plans” and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-

looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties,

many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially

from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other

things, the uncertainties inherent in research and development, future clinical data and analysis, including post-marketing, decisions by regulatory

authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any

such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such

product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and

commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing

interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those

discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under ”Risk Factors” and ”Cautionary Statement

Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable

law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Partnering Opportunities

For more information visit our website:

http://en.sanofi.com/partners/partners.aspx

www.sanofi.com

54, rue La Boétie

75008 Paris, France

partnering to advance global health - sanofi€¦ · digital page 13 gem general medicines &...

Documents